Navigation Links
Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care

oellex, the Company's lead compound, a PRM (progesterone receptor modulator) has recently completed a successful U.S. three-month Phase 2 clinical trial for the treatment of uterine fibroids, a condition that affects numerous women of childbearing age in the United States and results in a significant number of hysterectomies each year. Proellex has recently completed a six-month European Phase 1/2 study for the treatment of endometriosis, a condition that affects approximately 5.5 million women in the United States and Canada. Androxal(TM), the Company's other program in late clinical development, is designed to restore normal testosterone production by the testes in men and has recently completed a six-month U.S. non-pivotal Phase 3 clinical trial for the treatment of testosterone deficiency due to secondary hypogonadism. According to industry sources, approximately 13 million men in the United States experience testosterone deficiency. The Company is planning meetings with the FDA for all three programs to lay out the remaining clinical program pathway required before a New Drug Application may be submitted for each product candidate.

For more information, please visit the Company's website at http://www.reprosrx.com.

Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Repros' ability to have success in the clinical development of its technologies, the timing of enrollment in such clinical studies and the accuracy of such studies, Repros' ability to raise additional capital on acceptable terms or at all, and such other risks which are identified in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, and Repros' Quarterly Report on Form 10-Q for the quarter ended March 31, 2007, as they may be updated by the Company's Exchange Act filings from time to time. These documents are available on request from Repros Therapeutics or at
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
2. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
3. Repros Proellex Shows Statistically Significant Improvement in Primary Endpoint in Phase 2 Trial in the Treatment of Uterine Fibroids
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
(Date:8/29/2014)... 29, 2014 Thoratec Corporation (NASDAQ: ... support therapies to save, support and restore failing hearts, ... Morgan Stanley Global Healthcare Conference on Wednesday, September 10. ... Chief Executive Officer, will provide an update on the ... a.m., Pacific Daylight Time).   A webcast ...
(Date:8/29/2014)... WEST JORDAN, Utah , Aug. 29, 2014 /PRNewswire/ ... Imaging Solutions, has acquired Polaris Medical Imaging, a leader ... CT scanners. This strategic acquisition allows BC Technical to ... their capabilities, specifically within MR and CT modalities. ... lower cost service," said Mark Alvarez , president ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Instrument Industry Report, 2014-2017" report to their offering. ... rising proportion of reimbursement for medical expenses, the Chinese ... its scale presenting a CAGR of 19.2% during 2009-2013. ... product segments of orthopedic instruments in China ...
Breaking Medicine Technology:BC Technical Acquires Polaris Medical Imaging 2China Orthopedic Instrument Industry Report, 2014-2017 2
... Second Generation Oxazolidinone Demonstrates Safety and Efficacy with Once-Daily, ... of Treatment , , SAN DIEGO, June ... its Phase 2 clinical trial evaluating the safety and ... the treatment of severe complicated skin and skin structure ...
... sets to be released-- , , PARIS, ... in patients with blepharospasm and cervical dystonia -- one placebo-controlled ... presented at the Movement Disorder Society (MDS) 13th annual International ... Pharmaceuticals, which plans to file a Biologic License Application (BLA) ...
Cached Medicine Technology:Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections 2Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections 3Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections 4Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 2Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 3Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 4
(Date:8/29/2014)... New York, New York (PRWEB) August 29, 2014 ... died from cardiac arrest following a series of dialysis ... that alleges her death was the result of ... Liebhard LLP reports. The family’s lawsuit, which was file ... 2014, claims that the use of the products resulted ...
(Date:8/29/2014)... 2014 A team of experts from ... on its way to the 2014 National Safety Council ... Center to exhibit and demonstrate a suite of healthy ... environments. Etymotic’s safety earphones and high-definition earplugs are expected ... the show. , The company’s HD5 high-definition, noise-isolating ...
(Date:8/29/2014)... 2014) A team of scientists from the University ... discovery of a process to expand production of stem ... have implications that extend beyond cancer, including treatments for ... an article published Aug. 29 in ... Center for Regenerative Medicine and Stem Cell Biology and ...
(Date:8/29/2014)... D.C. (PRWEB) August 29, 2014 Today, ... Community Anti-Drug Coalitions of America (CADCA) , the nation’s ... in response to President Obama’s intent to nominate Michael ... , “CADCA strongly supports President Obama’s decision to nominate ... is the ideal person to hold this important position ...
(Date:8/29/2014)... According to the Chicago Tribune, ... next month for medical marijuana, regulators, businesses, cultivators, ... as a legalized medicine. New marijuana policies address ... to operate in accordance with local government, as ... to handle legal cannabis. , Restrictions concerning ...
Breaking Medicine News(10 mins):Health News:GranuFlo Lawsuit News: Family Alleges Woman’s Death Following Dialysis Was Caused by GranuFlo and NaturaLyte, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuit News: Family Alleges Woman’s Death Following Dialysis Was Caused by GranuFlo and NaturaLyte, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuit News: Family Alleges Woman’s Death Following Dialysis Was Caused by GranuFlo and NaturaLyte, Bernstein Liebhard LLP Reports 4Health News:Etymotic’s Safe Listening Earphones and Earplugs Headed For The 2014 NSC Safety Expo 2Health News:CU scientists' discovery could lead to new cancer treatment 2Health News:CADCA Statement on Nomination of Michael Botticelli as U.S. Drug Czar 2Health News:Medical Marijuana Approaches Legalization in Chicago 2
... , NEW YORK, Sept. 22 Reportlinker.com ... in its catalogue. , , ... and Healthcare Transaction Processing, 3rd Edition , The ... , , The North American market ...
... News media and scientists interested in finance, entrepreneurships and ... Chemical Society (ACS) Small & Medium Business Webinar on ... ) Small Business Innovation Research (SBIR) priority funding ... 24, 2 3 p.m. Eastern Time, the webinar ...
... think the air outside is polluted, a new research report ... ( http://www.genetics.org ) might make you to think twice ... show how about 3 percent of the air we breathe ... Specifically, these superoxides lead to the creation of a toxic ...
... BRYAN, Ohio, Sept. 22 For most ... more and more children are diagnosed with allergies and intolerances to ... leave many kids feeling left out. Spangler Candy Company ... inviting kids back in on all the fun. , , ...
... , MERRIAM, Kan., Sept. 22 ... . ." t-shirts to be auctioned off to benefit Christina ... National Denim Day on October 2, one of the largest single ... To view the Multimedia News Release, go to: ...
... CEDAR KNOLLS, N.J., Sept. 22 ScienceFirst is ... as a result of ScienceFirst,s sustained annual growth. , ... senior account director at ScienceFirst, where he will be ... delivery. Before joining ScienceFirst, Steen held the position of ...
Cached Medicine News:Health News:Reportlinker Adds North American Market for Third Party Payroll, Payment and Healthcare Transaction Processing, 3rd Edition , The Report 2Health News:Reportlinker Adds North American Market for Third Party Payroll, Payment and Healthcare Transaction Processing, 3rd Edition , The Report 3Health News:Reportlinker Adds North American Market for Third Party Payroll, Payment and Healthcare Transaction Processing, 3rd Edition , The Report 4Health News:Reportlinker Adds North American Market for Third Party Payroll, Payment and Healthcare Transaction Processing, 3rd Edition , The Report 5Health News:Reportlinker Adds North American Market for Third Party Payroll, Payment and Healthcare Transaction Processing, 3rd Edition , The Report 6Health News:Reportlinker Adds North American Market for Third Party Payroll, Payment and Healthcare Transaction Processing, 3rd Edition , The Report 7Health News:Reportlinker Adds North American Market for Third Party Payroll, Payment and Healthcare Transaction Processing, 3rd Edition , The Report 8Health News:Reportlinker Adds North American Market for Third Party Payroll, Payment and Healthcare Transaction Processing, 3rd Edition , The Report 9Health News:Reportlinker Adds North American Market for Third Party Payroll, Payment and Healthcare Transaction Processing, 3rd Edition , The Report 10Health News:Reportlinker Adds North American Market for Third Party Payroll, Payment and Healthcare Transaction Processing, 3rd Edition , The Report 11Health News:New research provides new insight into age-related muscle decline 2Health News:Spangler Helps Children with Food Allergies and Intolerances Enjoy a Worry-Free Halloween 2Health News:Video: Celebrities Join Christina Applegate to Share Their Heart for Breast Cancer Awareness 2Health News:Video: Celebrities Join Christina Applegate to Share Their Heart for Breast Cancer Awareness 3Health News:Video: Celebrities Join Christina Applegate to Share Their Heart for Breast Cancer Awareness 4
... 25,000 units Penicillin/25,000 ... Cell Culture Reagent and ... in accordance with cGMP ... culture tested to assure ...
Penicillin-Streptomycin-Glutamine (100X) liquid...
Penicillin-Streptomycin liquid...
... combination of penicillin and streptomycin which ... and gram negative bacteria when used ... I.U. Penicillin/100,000 g/mL Streptomycin per liter. ... water at concentrations of 5,000 I.U. ...
Medicine Products: